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Objectives: This study aimed to determine the overall survival (OS) and progression-free
interval and the influence of fertility-preserving surgery (FPS) versus radical surgery (RS) in
patients with serous borderline ovarian tumor (BOT).
Methods: Clinical parameters of patients with serous BOT treated between 1993 and 2013
in one institution were retrospectively investigated. All tumors were examined by one pa-
thologist with experience in gynecological pathology.
Results: One hundred thirty-two patients with serous BOT (inclusive 16 microinvasive)
were analyzed (45% were e40 years), with a median follow-up of 6 years. Thirty-two
percent (42/132) of the patients received FPS; 14% (18/132) relapsed (invasive or bor-
derline). The 5-year progression-free survival was 89%. The risk of recurrence was higher in
patients 40 years or younger (P = 0.019), after FPS (P = 0.002), in patients with a higher
International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.016), for bi-
lateral BOT (P = 0.0132), and for the micropapillary variant (P = 0.067). The OS at 5 years
was 97%. There was no statistically significant difference in OS between FPS and RS [all (6
of 90) patients, except for 1, with RS died]. One patient died of relapsed BOT. Among the
recurrences, low-grade invasive carcinoma was diagnosed in 4 patients. Three of these 4
patients were originally operated radically, 2 had a micropapillary variant FIGO stage III,
and 1 had a papillary pattern FIGO stage II with microinvasion; all 3 had noninvasive
implants and are alive. One patient with a micropapillary variant, FIGO stage IIIC with
microinvasion and invasive implants, received FPS and died of disease.
Conclusions: The risk of recurrence is higher after FPS compared with RS; however, no
influence on OS was observed. This was because most of the patients relapsed as BOT.
Fertility preservation is justified in young patients with serous borderline tumors.
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Serous borderline ovarian tumors (BOTs) represent 5% to10% of all ovarian epithelial tumors and are the most
common histologic subtype of BOT (53.3%).1,2 In contrast to
invasive ovarian cancer, they are characterized by the absence
of stromal invasion. Serous BOTs are divided into typical
(papillary) serous BOT (90%) and borderline tumor with
micropapillary pattern (5%Y10%).2 A subgroup of BOTs
presents microinvasion (10%).3 One third of the patients di-
agnosed with BOTs are younger than 40 years with an average
age of 42 years for serous BOT.1,4,5 Therefore, fertility-
preserving surgery (FPS) has become an important issue.5
The overall survival (OS) of serous BOTs is excellent with
5-year survival rates between 88% and greater than 95% for
International Federation of Gynecology and Obstetrics (FIGO)
stages I to IIIB.1 Despite these favorable data, approximately
11% of the patients with BOT relapse, with a risk for invasive
recurrence of 2% to 4%.2 Fertility-preserving surgery and
younger age are risk factors for recurrence.5,6 However, little is
known about the risk of invasive recurrence, and hence, the
impact of FPS on OS.6 The aim of this study was to determine
the OS and progression-free survival (PFS) and the influence
of FPS in a large group of patients with serous BOT, diagnosed
by one pathologist and treated by the same team during the
accrual period.
METHODS
Patients and Pathology
Clinical parameters of patients with serous BOT treated
between 1993 and 2013 in one institution were retrospectively
investigated. Only patients with a primary diagnosis of BOT
were included. This retrospective study was approved by the
institutional ethical committee of the University Hospitals
Leuven. All tumors were examined by one pathologist (P.M.),
who has an experience in gynecological pathology. The
micropapillary variant of serous BOTwas defined as a tumor
with very long micropapillae (95 times longer than wide) or
cribriform growth, in an area measuring more than 5 mm in
greatest dimension. A microinvasive tumor has one or several
foci of infiltrative (‘‘destructive’’) stromal invasion, measur-
ing less than 5 mm in greatest dimension or less than 10 mm2
in greatest area. The 2014 FIGO classification was used for
staging.7
Treatment and Recurrence
Radical surgery (RS) was defined as removal of both
ovaries with or without removal of the uterus combined with
complete surgical staging. Complete surgical staging was
defined as inspection (and palpation) of the entire abdominal
cavity, omentectomy with peritoneal biopsies, and cytology
and biopsies of any suspicious lesion. Standard lymphade-
nectomy was not included in complete surgical staging be-
cause there is no proven benefit in ovarian borderline tumors.8
Fertility-preserving surgery is considered as preservation of
the uterus and ovarian tissue in one or both adnexa with com-
plete surgical staging. The term recurrence implied invasive or
borderline recurrence. Borderline lesions in extraovarian tissue
with or without microinvasion or noninvasive implants were
defined as borderline recurrence. Presence of borderline lesions
in the contralateral ovarywasdefinedas contralateral borderline
recurrence, andwhen located in the ipsilateral ovary,we defined
this as persistent disease. Follow-up included clinical exami-
nation, vaginal ultrasound, and CA 125 measurements every
3 months during the first 2 years, every 6 months for the third
through 5 years, and yearly thereafter.
Statistical Analysis
The principal goal for this analysis was the OS and PFS.
Overall survival is the time from the date of diagnosis to the
date of death or last follow-up. The PFS was defined as the
time between diagnosis and invasive recurrence or borderline
recurrence. In case of persistent disease, the PFS is defined as
the time between diagnosis and diagnosis of persistent disease
in the ipsilateral ovary. Estimates of PFS and OS were based
on the KaplanYMeier method. Patients alive without recur-
rence or persistent disease were censored at the last follow-up;
patients who died without progression were censored at the
time of death.
The log-rank test was used to evaluate the difference
between FPS and RS on PFS and OS. The Cox proportional
hazards model was used to test the prognostic value of vari-
ables on PFS. Results are presented as hazard ratio (HR) with
95% confidence interval (CI). All tests are 2-sided, a 5%
significance level is assumed for all tests. Fisher exact test was
used to compare categorical variables between the 2 age
groups. All analyses have been performed using SAS soft-
ware, version 9.4 of the SAS systemWindows (SAS Institute,
Inc, Cary, NC).
RESULTS
Patient, Tumor, and Treatment
Characteristics
A total of 132 patients with the first diagnosis of serous
BOTwere analyzed. Median age was 45 years (17Y85 years)
with 60 patients 40 years or younger (45%) and 72 patients
older than 40 years (55%). The median follow-up was 6 years
(range, 3.8Y11.1 years).
Most patients were diagnosed with FIGO stage I (86 of
132). Peritoneal implants occurred in 34% (45 of 132) of
patients and were statistically more frequent in patients
40 years or younger (45% vs 25%, P = 0.013). Ten percent (14
of 132) had a micropapillary variant of which 3 relapsed as a
low-grade invasive carcinoma and 1 in the contralateral ovary
as BOT. Three were associated with noninvasive and 1 with
invasive implants. Ten of the 18 relapses were associated with
peritoneal implants. Ten (71%) of the patients with a micro-
papillary variant were diagnosed with peritoneal implants.
Three had invasive and 7 had noninvasive implants. Fertility-
preserving surgery was carried out in 32% (42 of 132) of all
patients and in 37 of the 60 patients 40 years or younger
(62% vs 7%, P G 0.001). In the 42 patients, 74% (31) had a
unilateral salpingo-oophorectomy (USO), 17% (7) had a USO
with contralateral cystectomy, and 9% (4) had a cystectomy
only. Radical surgery was carried out in 68% (90/132) of
the patients and in 23 of 60 patients 40 years or younger
(38% vs 93%, P G 0.001). Detailed patient, tumor, and
treatment-related parameters are provided in Table 1.
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TABLE 1. Patient, tumor, and treatment characteristics
Total (%), n = 132 Age e 40 y (%), n = 60 Age 9 40 y (%), n = 72 P
Median age, y 45 (17Y85) 27 (17Y40) 54 (42Y85) V
Micropapillary patterns 14/132 (10%) 6/60 (10%) 8/72 (11%) 1.000
Microinvasion 16/132 (12%) 7/60 (12%) 9/72 (12%) 1.000
FIGO stage
I 86/132 (65%) 32/60 (53%) 54/72 (75%) 0.011
IA 56/132 (42%) 21/60 (35%) 35/72 (49%)
IB 5/132 (4%) 2/60 (3%) 3/72 (4%)
IC 25/132 (19%) 9/60 (15%) 16/72 (22%)
II/III 45/132 (34%) 28/60 (47%) 18/72 (25%)
Unknown 1/132 (1%) 1/60 (2%) 0/72 (0%)
Peritoneal implants 0.013
No 86/132 (65%) 32/60 (53%) 54/72 (75%)
Yes 45/132 (34%) 27/60 (45%) 18/72 (25%)
Unknown 1/132 (0.76%) 1/60 (2%) 0/72 (0%)
Unilateral vs bilateral BOT 0.313
Unilateral 84/132 (64%) 35/60 (58%) 49/72 (68%)
Bilateral 47/132 (36%) 24/60 (40%) 23/72 (32%)
Primary surgical approach 0.277
Laparoscopy 20/132 (15%) 11/60 (18%) 9/72 (12.5%)
Laparotomy 111/132 (84%) 48/60 (80%) 63/72 (87.5%)
Unknown 1/132 (0.76%) 1/60 (2%) 0/72 (0%)
Surgical interventions G0.001
Radical 90/132 (68%) 23/60 (38%) 67/72 (93%)
Fertility-preserving 42/132 (32%) 37/60 (62%) 5/72 (7%)
FPS 0.534
USO 31/42 (74%) 27/35 (74%) 4/5 (80%)
USO + cystectomy 7/42 (17%) 7/35 (18%) 0/5 (0%)
Cystectomy 4/42 (9%) 3/35 (6%) 1/5 (20%)
RS 0.846
BSO + HT 80/90 (89%) 20/23 (87%) 60/67 (90%)
BSO 6/90 (7%) 2/23 (9%) 4/67 (6%)
USO + HT 4/90 (4%) 1/23 (4%) 3/67 (4%)
Mean CA 125 preoperative, kU/L 410 406 413 0.174
Staging quality 0.233
Complete 95/132 (72%) 40/60 (67%) 55/72 (76%)
Incomplete 34/132 (26%) 17/60 (28%) 17/72 (24%)
Unknown 3/132 (2%) 3/60 (5%) 0/72 (0%)
Residual tumor V
Yes 1/132 (1%) 1/60 (2%) 0/72 (0%)
No 0/132 (0%) 0/60 (0%) 0/72 (0%)
Unknown 6/132 (5%) 5/60 (8%) 1/72 (1%)
Recurrence V
Yes 18/132 (14%) 13/60 (22%) 5/72 (7%)
No 114/132 (86%) 47/60 (78%) 67/71 (93%)
(Continued on next page)
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OS, PFS, and Recurrence
Of the 132 patients, 18 (14%) had recurrent disease, 4
had low-grade serous invasive carcinoma, and 14 had bor-
derline tumor. Nine (64%) of the 14 patients had a relapse in
the ovary (2 in the contralateral and 7 in the ipsilateral ovary).
Of the patients who relapsed in the ipsilateral ovary, 4 had, at
diagnosis, a cystectomy, and 3 had a USO. Both patients who
relapsed in the contralateral ovary had a USO at primary
diagnosis. Of the patients who relapsed as BOT in the ovary,
all 9 were 40 years or younger and 8 of them had FPS. Median
time to borderline recurrence and persistence disease was 36
and 47 months, respectively. The time to the 4 invasive re-
currences was, respectively, 23, 59, 83, and 147 months. The
OS at 5 years was 96% (Fig. 1). One patient died of relapsed
BOT and 1 patient died of relapsed low-grade invasive car-
cinoma. Five patients died of intercurrent disease (DICD).
Fertility-preserving surgery is associated with a higher rate of
recurrence compared with RS (P = 0.0006); however, these re-
currences were mostly as borderline tumor in the ovary (Fig. 2).
There is no statistically significant difference in OS between
FPS and RS (P = 0.314) (Fig. 3). Overall survival for patients
older than 40 years andwho hadRSwasworse (of the 7 patients
who died, 6 had RS and were older than 40 years). The 5-year
OS for patients older than 40 year is 94% versus 100% for
patients 40 years or younger. Three patients who relapsed as
low-grade invasive carcinoma are still alive 88, 134, and 147
months after the diagnosis. Recurrences followed a linear
time pattern and 3-, 5-, and 10-year PFS rates are 94% (95%
CI, 88Y97), 89% (95%CI, 81Y94), and 84% (95%CI, 74Y90)
(Fig. 4). The 5-year PFS for patients 40 years or younger was
80% (vs 97% for patients older than 40 years). Of all patients,
47 were diagnosed with bilateral BOTand 10 of them had FPS.
Six of them relapsed, 5 of the 6 as persistentBOTand 1 as a low-
grade invasive carcinoma. This last patient died of disease
(DOD) after 2 years. The 5-year PFS for the patients with bi-
lateral BOT and FPS is 38%. The 5-year OS is 100%.
Prognostic Factors for Recurrence
The risk of recurrence was statistically significantly
higher in patients 40 years or younger (940 vs e40 years; HR,
0.290; 0.103Y0.816; P = 0.0191), for patients who underwent
FPS (FPS vs RS; HR, 4.753; 1.783Y12.671; P = 0.0018), for
patients with a higher FIGO stage (II/III vs I; HR, 3.211;
1.242Y8.300; P = 0.0161), for patients with implants (invasive
or noninvasive) (implants vs no implants; HR, 2.968;
1.127Y7.815; P = 0.0277), for patients with bilateral BOT at
primary diagnosis (bilateral BOT vs unilateral BOT; HR,
3.536; 1.303Y9.600; P = 0.0132), and for patients with re-
sidual disease (residual disease vs no residual disease; HR,
27.952; 3.211Y250.275; P = 0.0029). Therewas only 1 patient
with residual disease who refused complete surgery due to
childwish. She relapsed as persistent BOT in the ipsilateral
ovary. There is a trend of higher risk for recurrence (but not
statistically significant) for patients with a micropapillary
pattern compared to the usual variant (micropapillary vs usual
variant; HR, 2.867; 0.927Y8.865; P = 0.0674). Incomplete
staging (complete vs incomplete; HR, 0.927; 0.334Y2.578;
P = 0.8848), laparoscopy (laparoscopy vs laparotomy; HR,
0.433; 0.057Y3.271; P = 0.4169), preoperative CA 125 (CA
125 above 1000 kU/L; HR, 1.005; 0.999Y1.012; P = 0.0998),
cystectomy (cystectomy vs USO; HR, 2.353; 0.664Y8.345;
P = 0.1852), and microinvasion (microinvasion vs no micro-
invasion; HR, 2.499; 0.814Y7.674; P = 0.1096) were no sta-
tistically significant risk factors for recurrence. Prognostic
factors are further detailed in Table 2. The number of events in
the data set was too low to fit a multivariable model. The dif-
ference in recurrence risk between the age groups was not
significant after correction for surgery (940 vs e40 years; HR,
0.579; 0.170Y1.978;P=0.3834).Analysis of prognostic factors
for invasive recurrence could not be performed because there
were only 4 cases of invasive recurrence. However, 2 of the
patients who relapsed as low-grade invasive carcinoma were
originally diagnosed as a micropapillary variant FIGO stage III
with noninvasive implants. Both have had RS at primary di-
agnosis with complete staging and without lymphadenectomy.
One patient was 40 years or younger and the other patient was
40 years or older. The third patient, older than 40 years, was
originally diagnosed as a papillary variant FIGO stage II with
noninvasive implants, microinvasion, and had RS. The fourth
patient was 40 years or younger and had a micropapillary
pattern FIGO stage IIIC with microinvasion and invasive im-
plants. This patient received FPS and DOD.
TABLE 1. (Continued)
Total (%), n = 132 Age e 40 y (%), n = 60 Age 9 40 y (%), n = 72 P
Nonovarian recurrence
Invasive recurrence 4/9 (44%) 2/4 (50%) 2/5 (40%)
Borderline recurrence 5/9 (56%) 2/4 (50%) 3/5 (60%)
Ovarian recurrence
Contralaterall 2/9 (22%) 2/9 (22%) 0/9 (0%)
Persistent 7/9 (78%) 7/9 (78%) 0/9 (0%)
Death 7/132 (5%) 1/60 (2%) 6/72 (8%) V
DOD 2/132 (1.5%) 1/60 (2%) 1/72 (1%)
Characteristics of patients 40 years or younger are compared to characteristics of patients older than 40 years.
BSO, Bilateral salpingo-oophorectomy; HT, total hysterectomy.
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Subgroup of Patients With Microinvasion
Microinvasion occurred in 12% of the patients (16/132).
Nine patients were older than 40 years and 9 patients were
diagnosedwith FIGO stage I. Six of 16 patientswere associated
with implants and 3 had a micropapillary pattern. Four of 16
patients had FPS. Four patients relapsed, 2 of them relapsed as
persistent BOT after FPS. Both were 40 years or younger and
were initially diagnosedwith FIGO stage I. The other 2 patients
relapsed as a low-grade invasive serous carcinoma. No differ-
ence in survival was observed between RS and FPS. Two pa-
tients died (1 DOD after FPS and 1 DICD after RS). The 5-year
PFS is 83% and the 5-year OS is 93%. Ten patients had a bi-
lateral BOT. Three of them received FPS and relapsed (2 as
persistent BOT and 1 as a low-grade invasive serous carcino-
ma). All were alive at the time of analysis.
DISCUSSION
A higher risk for recurrence after FPS compared with
RS has been described for a long time in literature.6,9,10 The
question that arises now is whether this translates into an
impaired patient survival. Uzan et al6 investigated prognostic
factors for invasive recurrence and the impact on OS after
FPS. Invasive recurrent disease is the only prognostic factor
that can influence patient survival.6,11 A higher risk for re-
currence after FPS compared to RS was confirmed but no
effect on OS was observed.6 Trillsch et al found a higher rate
of recurrence in younger patients usually in ovarian tissue,
without increased risk for malignant transformation. How-
ever, they observed a higher risk for invasive progression in
older patients.5
Our series of 132 patients confirmed the excellent
overall prognosis of BOTwith an OS rate of 96% at 5 years
and 91% at 10 years with a mean follow-up time of 6 years. Of
the 7 patients who died, 1 patient died of relapsed BOT and 1
patient died of a relapse as low-grade invasive carcinoma. The
first patient had a BOT stage III with noninvasive implants at
primary diagnosis and underwent RS with complete staging.
She relapsed as BOT with noninvasive implants on the liver
and peritoneum with a metastatic mediastinal lymph node for
BOT on fine needle aspiration cytology. She later developed
FIGURE 1. Overall survival curve for all patients. The
5-year OS is 97%. The dotted lines represent the 95%CI.
FIGURE 2. Progression-free survival curve by surgery.
The risk of progression is higher for patients who
underwent FPS compared to RS (P = 0.0006).
FIGURE 3. Influence of FPS vs RS on OS. There is no
statistically significant difference in OS between FPS
and RS (P = 0.3147).
FIGURE 4. Progression-free survival curve for all
patients. The 5-year PFS is 89%. The dotted lines
represent the 95% CI.
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ascites, pleural effusion, and brain metastasis. The relapse
including the brain metastasis and mediastinal lymph nodes
were probably due to transformation to an invasive cancer but
we did not obtain pathological proof of invasiveness. The
second patient was 40 years or younger and had a micropapillary
pattern FIGO stage IIIC with microinvasion and invasive
implants. She received FPS because of incomplete childwish
with adjuvant chemotherapy. She relapsed as a low-grade
invasive carcinoma with invasive implants in the abdomen,
pelvis, and lymph nodes. She died of respiratory insufficiency
due to bilateral malignant pleural effusion with infection. The
other 5 patients DICD. Six of 7 patients who died were older
than 40 years and had RS. The PFS curve showed a linear
decrease and the 10-year PFS was 84%, stressing the impor-
tance of long-term follow-up.12,13 We found an overall re-
currence rate of 14% (18 of 132), with an invasive recurrence
rate of 3% (4 of 132). Progression-free survival was worse in
patients 40 years or younger. Similar findings were reported
in other studies.2,5,14
We found a higher FIGO stage (III), peritoneal im-
plants, bilateral BOT, residual disease, fertility preservation,
and a younger age (e40 years) to be prognostic factors for
disease recurrence. There is a trend for a higher risk for pa-
tients with micropapillary type at primary diagnosis. No
statistically significant prognostic factors for invasive recur-
rence were found because only 4 cases relapsed as low-grade
invasive carcinoma. Although FPS is associated with a higher
rate of recurrence compared with RS, no effect on OS was
seen because most recurrences were borderline lesions that
were cured by a second surgical procedure.1,14 The 5-year OS
for patients 40 years or younger was 100%. Therefore, fertility-
preserving approach can be justified in young patients with
serous borderline tumors.6,15,16
Sixty-one percent of the patients 40 years or younger
had FPS with preservation of parts of a BOT-affected ovary in
25% of these cases. Patients with BOTwith childbearing po-
tential and FPS mainly relapse in the remaining ovarian tissue
without invasive malignant transformation.5 One exception in
our series was observed as outlined previously. Furthermore,
the study by Trillsch et al5 described a higher risk for malignant
transformation in older patients compared to younger patients.
No statistically significant conclusions could be made about
this matter in our series because of the low number of invasive
recurrences (only 4).
Micropapillary BOT has been described as being a
morphological variant of typical serous borderline ovarian tu-
mour, associated with higher incidences of poor prognostic
factors (higher FIGO stage, bilaterality, and ovarian surface
growth) but similar prognosis as typical serous borderline
ovarian tumours, rather than being a distinct clinical entity with
different prognosis or biological behavior.1,17,18Micropapillary
BOTs associated with invasive implants have a poorer prog-
nosis but invasive implants are rare.11 Micropapillary pattern
was considered as a risk factor for invasive recurrence after FPS
in the study of Uzan et al. However, the prognostic value is
limited because there was only one case with invasive relapse.6
In our series, prognostic value of this finding was also limited
due to low incidence of cases. A recent study of Vasconcelos
et al19 showed a higher risk for lethal recurrence for pa-
tients with a micropapillary pattern, regardless of stage, than
for patients with high-stage BOT.
In most studies, microinvasion has not been found as an
independent prognostic factor for (lethal) recurrence, but it
may be associated with higher incidences of poor prognostic
factors (extraovarian implants, micropapillary pattern, and
lymph node involvement).19,20 In our study, there was no
higher lethal recurrence rate for patients with microinvasion.
Only 1 patient with microinvasion died in our series. She had
a FIGO stage IIIC, micropapillary pattern, invasive implants,
and lymph node involvement at primary diagnosis and she
received FPS.
No adverse prognosis is shown in literature for nonin-
vasive implants, whereas invasive implants were associated
with shorter OS and higher recurrence rate, with a rate of
TABLE 2. Prognostic factors for recurrence (as borderline or invasive cancer)
95% CI
Variable HR Lower Limit Upper Limit P No. Obs. No. Events
Age: 940 vs e40 y 0.290 0.103 0.816 0.0191 132 18
Surgery: fertility-preserving vs radical 4.753 1.783 12.671 0.0018 132 18
Cystectomy vs USO 2.353 0.664 8.345 0.1852 40 11
Staging: complete vs incomplete 0.927 0.334 2.578 0.8848 129 17
FIGO: II/III vs I 3.211 1.242 8.300 0.0161 132 18
Laparoscopy vs laparotomy 0.433 0.057 3.271 0.4169 131 17
Micropapillary vs papillary 2.867 0.927 8.865 0.0674 132 18
Implants: yes vs no 2.968 1.127 7.815 0.0277 131 17
Bilateral BOT vs unilateral BOT 3.536 1.303 9.600 0.0132 131 17
Residual tumor: yes vs no 27.952 3.122 250.275 0.0029 126 12
Microinvasion: yes vs no 2.499 0.814 7.674 0.1096 132 18
CA 125 preoperative (9100 kU/l) 1.005 0.999 1.012 0.0998 92 11
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invasive recurrence of 38%.3,4,11,14,19,21,22 We could confirm
that presence of implants is a significant prognostic factor of
recurrence. However, there was no statistically significant
difference between the prognostic impact of invasive versus
noninvasive implants, probably due to limited case num-
bers.23 Presence of invasive implants did not interfere with
OS. In our series, one of the 3 patients with invasive implants
and micropapillary pattern relapsed as a low-grade invasive
carcinoma and died. The only prognostic factor of invasive
recurrence described in literature is disease stage (and the
implant subtype).11
Many studies find incomplete staging as a prognostic
factor for recurrence. We could not confirm this finding.
However, our study showed a higher rate of complete staging
(72%) compared with the literature (38%Y50%).4,14,24 Al-
though incomplete staging did not increase the risk for re-
currence, it is important to consider complete staging as a
preventive measure. A recent analysis of the AGO ROBOT
study concluded not only that incomplete surgical staging is
an independent negative risk factor for disease recurrence but
also that the risk of recurrence increases with each skipped
step of the surgical staging.23,25Y27 The impact on OS re-
mains, however, unproven.6,28
CONCLUSIONS
Serous BOTs have an excellent overall prognosis. There
is a higher risk for recurrence after FPS, for higher FIGO
stage, bilateral BOT, and for younger patients. There was no
statistical significant higher risk of recurrence in both age
groups for patients with microinvasion in our series. No effect
on OS was seen after FPS compared with RS. We observed
that patients with BOT with childbearing potential and FPS
relapse mainly in the remaining ovarian tissue without inva-
sive malignant transformation. Therefore, fertility-preserving
approach can be justified in young patients with serous bor-
derline tumors.
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